Table S4.
Univariate and multivariate analysis evaluating the relationship between favorable risk long-term responders and clinicopathological factors
| Univariate analysis | Multivariate analysis | |||||
|---|---|---|---|---|---|---|
| HR | 95% CI | P value | HR | 95% CI | P value | |
| Age > 70 | 0.59 | 0.15–2.25 | 0.44 | |||
| Gender, male | 1.82 | 0.61–5.36 | 0.27 | |||
| Histology clear-cell RCC | 0.26 | 0.03–1.78 | 0.17 | |||
| ECOG PS ≥ 1 | 0.67 | 0.28–1.61 | 0.37 | |||
| Previous nephrectomy, Yes | 0.60 | 0.000–1.5 | 0.99 | |||
| Sarcomatoid feature, Yes | 0.97 | 0.54–1.74 | 0.93 | |||
| Metastatic sites, n (%) | ||||||
| Lung | 1.26 | 0.5–3.13 | 0.61 | |||
| Liver | 0.18 | 0.02–1.47 | 0.11 | |||
| Nodal | 0.58 | 0.24–1.4 | 0.22 | |||
| Bone | 0.41 | 0.15–1.12 | 0.08 | |||
| Brain | 0.15 | 0.01–1.22 | 0.07 | 0.12 | 0.01–0.97 | 0.04 |
| Line of therapy after TKI > 1, n (%) | 0.5 | 0.21–1.19 | 0.11 | |||
ECOG PS: Eastern Cooperative Oncology Group Performance Status scale; RCC: Renal cell carcinoma; TKI: Tyrosine kinase inhibitor.